20Jan 2017

HELICOBACTER PYLORI ERADICATION EFFECT ON LIVER FAT CONTENT IN PATIENT WITH NON-ALCOHOLIC FATTY LIVER DISEASE.

  • Lecturer of internal medicine, faculty of medicine, Zagazig University.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background: Helicobacter pylori (HP) infection role in nonalcoholic fatty liver disease (NAFLD) pathogenesis is controversial. Aims: This study aimed to evaluate the effect of HP eradication on liver fat content (LFC), liver function tests (LFT), lipid profile, and homeostasis model assessment-IR (HOMA-IR) index in NAFLD. Patients and Methods: Patient with dyspepsia and increased serum levels of aminotransferases enrolled in the study. Exclusion criteria were factors affecting aminotransferases levels or HP treatment regimen. Patients with elevated aminotransferases levels and ultrasound findings of fatty liver disease were supposed for NAFLD. NAFLD liver fat score used to classify NAFLD, those with score greater than -0.64 and positive results for urea breath test (UBT), were included. Patients underwent lifestyle modifications and HP eradication. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), triglyceride (TG), cholesterol (CHOL), high and low-density lipoprotein (HDL, LDL), fasting serum glucose (FSG), LFC, and HOMA-IR were checked at baseline, after eight weeks and twenty four weeks. Results : One hundred twenty patients (58 males) with the mean age of 45.39 (±9.24) were included with repeated ANOVA measurement showed a significant reduction in anthropometric measurements , laboratory parameters (except for HDL) and LFC in both groups during the study; however, no significant difference was observed between the groups. Conclusions: HP eradication per se might not affect LFT, lipid profile, LFC, and insulin resistance in dyspeptic NAFLD patients

  1. Stalke P, Al-Soud WA, Bielawski KP, Bakowska A, Trocha H, Stepin­ski J, et al. Detection of Helicobacter species in liver and stomach tissues of patients with chronic liver diseases using polymerase chain reaction-denaturing gradient gel electrophoresis and im­munohistochemistry. Scand J Gastroenterol. 2005; 40(9):1032–41.
  2. Pirouz T, Zounubi L, Keivani H, Rakhshani N, Hormazdi M. De­tection of Helicobacter pylori in paraffin-embedded specimens from patients with chronic liver diseases, using the amplifica­tion method. Dig Dis Sci. 2009; 54(7):1456–9.
  3. Cindoruk M, Cirak MY, Unal S, Karakan T, Erkan G, Engin D, et al. Identification of Helicobacter species by 16S rDNA PCR and se­quence analysis in human liver samples from patients with vari­ous etiologies of benign liver diseases. Eur J Gastroenterol Hepatol. 2008; 20(1):33–6.
  4. Huang Y, Fan XG, Wang ZM, Zhou JH, Tian XF, Li N. Identification of helicobacter species in human liver samples from pa­tients with primary hepatocellular carcinoma. J Clin Pathol. 2004; 57(12):1273–7.
  5. Pellicano R, Menard A, Rizzetto M, Megraud F. Helicobacter spe­cies and liver diseases: association or causation? Lancet Infect Dis. 2008; 8(4):254–60.
  6. Taylor NS, Fox JG, Yan L. In-vitro hepatotoxic factor in Helico­bacter hepaticus, H. pylori and other Helicobacter species. J Med Microbiol. 1995; 42(1):48–52.
  7. Fukuda Y, Bamba H, Okui M, Tamura K, Tanida N, Satomi M, et al. Helicobacter pylori infection increases mucosal permeability of the stomach and intestine. Digestion. 2001; 63 Suppl 1:93–6.
  8. Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N, et al. Helicobacter pylori infection is significantly associated with metabolic syndrome in the Japanese population. Am J Gas­troenterol. 2008; 103(12):3005–10.
  9. Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N, et al. Helicobacter pylori infection significantly increases in­sulin resistance in the asymptomatic Japanese population. Heli­cobacter. 2009; 14(5):144–50.
  10. Nwokolo CU, Freshwater DA, O'Hare P, Randeva HS. Plasma ghre­lin following cure of Helicobacter pylori. Gut. 2003; 52(5):637–40.
  11. Wu MS, Lee WJ, Wang HH, Huang SP, Lin JT. A case-control study of association of Helicobacter pylori infection with morbid obesity in Taiwan. Arch Intern Med. 2005; 165(13):1552–5.
  12. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med. 2000; 342(17):1266–1271.
  13. Krier M, Ahmed A. The asymptomatic outpatient with abnormal liver function tests. Clin Liver Dis. 2009; 13(2):167-177.
  14. Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Berg­holm R, Johansson LM, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. 2009; 137(3):865–72.
  15. Fan JG, Jia JD, Li YM, Wang BY, Lu LG, Shi JP, et al. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepa­tology 2010; 18:163-166). J Dig Dis. 2011; 12(1):38–44.
  16. Suzuki A, Binks M, Sha R, Wachholtz A, Eisenson H, Diehl AM. Se­rum aminotransferase changes with significant weight loss: sex and age effects. Metabolism. 2010; 59(2):177–85.
  17. Fakheri H, Malekzadeh R, Merat S, Khatibian M, Fazel A, Alizadeh BZ, et al. Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a popula­tion with a high metronidazole resistance rate. Aliment Pharma­col Ther. 2001; 15(3):411–6.
  18. Razavizade M, Jamali R, Arj A, Talari H. Serum parameters predict the severity of ultrasonographic findings in non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int. 2012; 11(5):513–20.
  19. Jonaitis LV, Kiudelis G, Kupcinskas L. Evaluation of a novel 14C-urea breath test "Heliprobe" in diagnosis of Helicobacter pylori infection. Medicina (Kaunas). 2007; 43(1):32–5.
  20. Romero-Corral A, Somers VK, Sierra-Johnson J, Thomas RJ, Collazo- Clavell ML, Korinek J, et al. Accuracy of body mass index in diagnosing obesity in the adult general population. Int J Obes (Lond) 2008; 32:959-66.
  21. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA mod­eling. Diabetes Care. 2004; 27(6):1487–95.
  22. Dogan Z, Filik L, Ergul B, Sarikaya M, Akbal E. Association be­tween Helicobacter pylori and liver-to-spleen ratio: a random­ized-controlled single-blind study. Eur J Gastroenterol Hepatol. 2013; 25(1):107–10.
  23. Ponzetto A, Pellicano R, Leone N, Cutufia MA, Turrini F, Grigioni WF, et al. Helicobacter infection and cirrhosis in hepatitis C virus carriage: is it an innocent bystander or a troublemaker? Med Hy­potheses. 2000; 54(2):275–7.
  24. Leone N, Pellicano R, Brunello F, Cutufia MA, Berrutti M, Fa­goonee S, et al. Helicobacter pylori seroprevalence in patients with cirrhosis of the liver and hepatocellular carcinoma. Cancer Detect Prev. 2003; 27(6):494–7.
  25. Takuma Y. [Helicobacter pylori infection and liver diseases]. Gan to Kagaku Ryoho. 2011; 38(3):362–4.
  26. Polyzos SA, Kountouras J, Papatheodorou A, Patsiaoura K, Katsiki E, Zafeiriadou E, et al. Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism. 2013; 62(1):121–6.
  27. Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, et al. Effect of a probiotic on liver aminotransferases in nonal­coholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011; 15(9):1090–5.
  28. Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol. 2003; 38(5):681–7.
  29. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010; 51(1):121–9.
  30. Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, Rothwell A, et al. Metabolic profiling reveals a contribution of gut micro­biota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A. 2006; 103(33):12511–6.

[Ahmed H. Arnaout. (2017); HELICOBACTER PYLORI ERADICATION EFFECT ON LIVER FAT CONTENT IN PATIENT WITH NON-ALCOHOLIC FATTY LIVER DISEASE. Int. J. of Adv. Res. 5 (Jan). 1547-1553] (ISSN 2320-5407). www.journalijar.com

Ahmed Hamouda Ali Arnaout
Zagazig University, Faculty of Medicine, Internal Medicine Department

DOI:

Article DOI: 10.21474/IJAR01/2919      
DOI URL: https://dx.doi.org/10.21474/IJAR01/2919

Download Full Paper

Download PDF No. of Downloads: 11 | No. of Views: 92